Zavesca
Miglustat, N-Butyldeoxynojirimycin (NB-DNJ)
- User: Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Permanent
- Development Stage: Discovery & Early Development
- Developer(s)/researcher(s): University of Washington, Oxford GlycoSciences
Details
- API: Miglustat
- Target: Glucosylceramide Synthase
-
Mechanism of Action:
- Reduced Sperm Production
- Inactive Materials: Sodium starch Glycolate, Povidone (K30), Magnesium Stearate
- Regimen: Not Determined
- MPT: Not Potential MPT
Product Status
Development discontinued after evaluation indicating no apparent effect on sperm production
History
While Miglustat/Zavesca, a medication used to treat Gaucher disease, was found to cause reversible infertility in mice, pilot studies in humans found no apparent effect.